# Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Canonical URL: https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-health-care-conference
Ticker: MLYS
Company: Mineralys Therapeutics
Source: Mineralys Therapeutics
Published: 2026-05-05 12:00 EST
Original Source URL: https://ir.mineralystx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-14 14:00 EST — [Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-and-heart-fai-35eaa6f1) — Source: Mineralys Therapeutics
- 2026-06-08 20:05 EST — [Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-he-6027ff68) — Source: Mineralys Therapeutics
- 2026-06-08 11:00 EST — [Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-present-late-breaking-data-on-lorundrostat-at-the-endo-03fb3c48) — Source: Mineralys Therapeutics
- 2026-06-03 10:05 EST — [Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-pricing-of-150-million-underwritten-offering-of-common-stock) — Source: Mineralys Therapeutics
- 2026-06-03 10:00 EST — [Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-repurchase-of-royalty-obligations-in-tanabe-license-agreement-and-concurrent-financing) — Source: Mineralys Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)